Utah expands AI sandbox for prescription drug pilots — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Utah regulators announced a plan allowing AI to evaluate patients for mild-to-moderate acne and write new drug prescriptions without prior human review.
- Nolla Health will launch the service, assessing patients via structured intake and skin photo analysis to determine if one of a list of low-risk drugs is appropriate; the startup raised $4.5 million from investors including General Catalyst last year.
- The pilot starts with licensed clinician sign-off on AI-generated prescriptions, but Nolla may eventually be permitted to prescribe without any human review.
- The expansion is part of Utah's 'AI sandbox' run by the Office of Artificial Intelligence Policy (OAIP), which can waive state regulations including those governing the practice of medicine.
- Nolla Health aspires to direct AI-driven treatment for a broad range of conditions beyond acne as the sandbox matures.
Why it matters: Utah's 'AI sandbox' is the regulatory vehicle here — it lets the state waive practice-of-medicine rules, and the Nolla pilot deliberately starts with a constrained list of low-risk acne drugs and a clinician-review off-ramp before potentially moving to fully autonomous prescribing, making it a closely watched testbed other states may look to as a template for AI prescribing governance.
Ask SkimNews
